Compare Novartis AG (NVS) vs TKO Group Holdings Inc (TKO) Price & Performance

Novartis AGTrade

TKO Group Holdings IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs TKO Group Holdings Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while TKO Group Holdings Inc trades at $181.83 (market cap $13.70B). The key difference: Novartis AG is far larger — about 21.2× TKO Group Holdings Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVS	TKO
Market Cap	$290.25B	$13.70B
Sector	Health	Technology
52-Week High	$168.62	$224.96
52-Week Low	$113.50	$155.61
Enterprise Value	$330.27B	$17.88B
Dividend Yield	3.17%	1.7%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.

The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.

TKO Group Holdings Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 5 days agoBullish View details →

TKO

Meridianbet named official UFC Fight Night Serbia partner for August 2026 event, marking UFC's Serbia debut.GlobeNewsWire · 4 days agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About TKO Group Holdings Inc

TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.